Sunil Anklekar’s commentary on the current topics in radiodiagnostic and radiotherapeutic nuclear medicines from a chemist’s perspective. This is an independent blog, and all opinions expressed are his own. The blog contents are for informational purpose only and should not be taken as a professional advice. For questions or comments on blogs, please email him at pharmafronts.author@gmail.com
ITM’s NDA Accepted for Lu-177 GEP-NET Drug ITM-11
ITM Isotope Technologies Munich (ITM), announced on Nov. 13 that the U.S. FDA has accepted the company’s NDA for n.c.a. 177Lu-edotreotide (ITM-11, 177Lu-edotreotide), a targeted radiotherapeutic investigational agent for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Edotreotide is a synthetic form of somatostatin hormone and binds with high affinity to somatostatin receptors (SSTRs) expressed on tumor cells,
F-18 Flurcardo (Flurpiridaz), a Breakthrough PET Imaging for CAD
Coronary artery disease (CAD) is a leading cause of death worldwide, and requires precise, accessible, and versatile diagnostic imaging agents. Myocardial perfusion imaging (MPI) plays a central role in evaluating CAD, guiding treatment decisions, and identifying risk level. While SPECT agents like Tc-99m ( e.g. Sestamibi) have been in use for a long time, PET
Nuclear Medicine Imaging Stocks: Price Dip Analysis
Several leading companies in the nuclear medicine targeted imaging space have seen their stock valuations decline in recent quarter, despite continued clinical progress. Stock prices of companies like Lantheus Holdings, Telix Pharmaceuticals, and Clarity Pharmaceuticals have taken a hit, but beneath the surface, pipeline progress remains strong. For investors with a long-term horizon, this valuation
a dual Target theranostic radioligand for Prostate Cancer
Introduction Current oncology radiopharmaceutical therapies rely on a single biomarker target to deliver cytotoxic radiation to tumors. However, tumor heterogeneity and receptor variability often limit efficacy of these radiotherapeutics. Dual-biomarker targeting radiopharmaceuticals are the next class of radioligands designed to simultaneously bind to two distinct tumor-associated biomarkers, and is expected to enhance imaging sensitivity and
SNMMI’s AI Trial Finder: Facilitating Patient Access to Radiopharmaceutical Clinical Trials
On August 11, 2025, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) introduced the “Global Radiopharmaceutical Clinical Trials Finder”, an AI-supported platform designed to make patient enrollment in nuclear medicine clinical trials easier and efficient for patients worldwide. The interface asks patients about the condition, prior treatments, ZIP code/city of residence, and generates a
ITM’s NDA Accepted for Lu-177 GEP-NET Drug ITM-11
ITM Isotope Technologies Munich (ITM), announced on Nov. 13 that the U.S. FDA has accepted the company’s NDA for n.c.a. 177Lu-edotreotide (ITM-11, 177Lu-edotreotide), a targeted radiotherapeutic investigational agent for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Edotreotide is a synthetic form of somatostatin hormone and binds with high affinity to somatostatin receptors (SSTRs) expressed on tumor cells,
F-18 Flurcardo (Flurpiridaz), a Breakthrough PET Imaging for CAD
Coronary artery disease (CAD) is a leading cause of death worldwide, and requires precise, accessible, and versatile diagnostic imaging agents. Myocardial perfusion imaging (MPI) plays a central role in evaluating CAD, guiding treatment decisions, and identifying risk level. While SPECT agents like Tc-99m ( e.g. Sestamibi) have been in use for a long time, PET
Nuclear Medicine Imaging Stocks: Price Dip Analysis
Several leading companies in the nuclear medicine targeted imaging space have seen their stock valuations decline in recent quarter, despite continued clinical progress. Stock prices of companies like Lantheus Holdings, Telix Pharmaceuticals, and Clarity Pharmaceuticals have taken a hit, but beneath the surface, pipeline progress remains strong. For investors with a long-term horizon, this valuation
a dual Target theranostic radioligand for Prostate Cancer
Introduction Current oncology radiopharmaceutical therapies rely on a single biomarker target to deliver cytotoxic radiation to tumors. However, tumor heterogeneity and receptor variability often limit efficacy of these radiotherapeutics. Dual-biomarker targeting radiopharmaceuticals are the next class of radioligands designed to simultaneously bind to two distinct tumor-associated biomarkers, and is expected to enhance imaging sensitivity and
SNMMI’s AI Trial Finder: Facilitating Patient Access to Radiopharmaceutical Clinical Trials
On August 11, 2025, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) introduced the “Global Radiopharmaceutical Clinical Trials Finder”, an AI-supported platform designed to make patient enrollment in nuclear medicine clinical trials easier and efficient for patients worldwide. The interface asks patients about the condition, prior treatments, ZIP code/city of residence, and generates a
Download
Complimentary eReport
“Supply Chain Logistics For A PET Radiotracer Manufacture”
Supply chain for an 18F radioisotope based PET radiotracer manufacture is discussed in detail along with brief manufacturing descriptions provided for context. A critical report for supply chain, manufacturing, business and investing personnel to familiarize with the basics of supply chain for this category of high application, commercially critical PET diagnostic imaging agents.
Click the icon below to download the free report.
Categories
Archives
Like to receive in-depth analysis on radiopharmaceuticals straight to your inbox?
(Emails are kept strictly confidential)